Onkologie最新文献_第4页

Vemurafenib-induced pulmonary injury. vemurafenib诱导的肺损伤。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-10-14 DOI: 10.1159/000355643

Laurenz Schmitt, Tamara Schumann, Christoph Löser, Edgar Dippel

引用次数: 5

Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study. 依维莫司在初始血管内皮生长因子受体酪氨酸激酶抑制剂(VEGFr-TKI)治疗失败后的转移性肾细胞癌:一项非介入性研究的中期分析结果。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-02-25 DOI: 10.1159/000348522

Lothar Bergmann, Peter J Goebell, Ulrich Kube, Manfred Kindler, Edwin Herrmann, Jan Janssen, Joerg Schmitz, Steffen Weikert, Gabriel Steiner, Andreas Jakob, Michael D Staehler, Thomas Steiner, Friedrich Overkamp, Michael Albrecht, Gernot Guderian, Christian Doehn

{"title":"Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.","authors":"Lothar Bergmann, Peter J Goebell, Ulrich Kube, Manfred Kindler, Edwin Herrmann, Jan Janssen, Joerg Schmitz, Steffen Weikert, Gabriel Steiner, Andreas Jakob, Michael D Staehler, Thomas Steiner, Friedrich Overkamp, Michael Albrecht, Gernot Guderian, Christian Doehn","doi":"10.1159/000348522","DOIUrl":"https://doi.org/10.1159/000348522","url":null,"abstract":"Background: Everolimus is approved for treatment of anti-vascular endothelial growth factor (VEGF)-refractory patients with metastatic renal cell carcinoma (mRCC). Clinical trials rarely mirror treatment reality. Thus, a broader evaluation of everolimus is valuable for routine use.Patients and methods: A German multicenter non-interventional study documented mRCC patients starting everolimus after failure of initial VEGF-targeted therapy. Primary endpoint was effectiveness, defined as time to progression (TTP) according to investigator assessment (time from first dose to progression).Results: Of 382 documented patients, 196 were included in this interim analysis. In the efficacy population (n = 165), median TTP was 7.0 months (95% confidence interval (CI) 5.1-9.0). Among patients with < or ≥ 6 months of previous VEGF-targeted therapy, median TTP was 6.6 months (95% CI 3.8-not estimable) and 7.4 months (95% CI 4.6-9.6), respectively. Most common adverse events were anemia (13%) and dyspnea (14%). Physicians assessed high tolerance and documented high adherence to everolimus therapy (approximately 97%).Conclusion: In routine clinical practice, everolimus is effective, as measured by median TTP (longer than median progression-free survival in RECORD-1 trial), and well tolerated. Our results support everolimus use in anti-VEGF-refractory patients with mRCC.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 3","pages":"95-100"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000348522","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31303970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Supportive therapy and rehabilitation for cancer. Abstracts of the 3rd ASORS Annual Congress. April 12-13, 2013. Berlin, Germany. 癌症的支持性治疗和康复。第三届ASORS年会摘要。2013年4月12日至13日。德国柏林。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-04-05 DOI: 10.1159/000190043

引用次数: 0

Overexpression of the Hedgehog signalling pathway in head and neck squamous cell carcinoma. 刺猬信号通路在头颈部鳞状细胞癌中的过表达。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-03-28 DOI: 10.1159/000350322

Kamelia Dimitrova, Matthaeus Stoehr, Faramarz Dehghani, Andreas Dietz, Gunnar Wichmann, Julia Bertolini, Christian Mozet

{"title":"Overexpression of the Hedgehog signalling pathway in head and neck squamous cell carcinoma.","authors":"Kamelia Dimitrova, Matthaeus Stoehr, Faramarz Dehghani, Andreas Dietz, Gunnar Wichmann, Julia Bertolini, Christian Mozet","doi":"10.1159/000350322","DOIUrl":"https://doi.org/10.1159/000350322","url":null,"abstract":"Background: Overexpression of the Hedgehog (HH) signalling pathway has been described in several malignancies and is associated with a poor prognosis. HH signalling blockade reduces tumour growth in vitro and in vivo. We aimed to determine whether head and neck squamous cell carcinomas (HNSCCs) express HH proteins in comparison to healthy mucosa.Patients and methods: Formalin-fixed and paraffin-embedded tissue sections of 10 patients with HNSCC were stained with fluorescence-labelled antibodies for cytokeratin and HH proteins (SHH, PTCH1/2, SMO, Gli1-3) and photographs were taken with a laser scanning microscope. The pixel count and colour intensity were analysed in RGB (red/green/blue) colour mode, and expression levels were compared to healthy mucosa.Results: Image analysis in RGB mode provided objective evidence for the over-expression of HH signalling components in HNSCC, particularly with regard to the transcription factors Gli1 (10-fold) and SHH (5-fold) in comparison with healthy mucosa. The lowest levels were found for Gli3 in HNSCC.Conclusions: We postulate pivotal roles of Gli1 and SHH expression in the carcinogenesis of HNSCC. HH pathway overexpression appears to be involved in the initiation of tumour growth and spread due to its stem cell-modulating properties. Detection of HH pathway components, and especially Gli1 and SHH, in HNSCC might offer a promising target for further anticancer research in HNSCC.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 5","pages":"279-86"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000350322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31443254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer - own findings and review of the literature. 辅助治疗降低了播散性乳腺癌姑息治疗的益处——自己的发现和文献综述。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-05-21 DOI: 10.1159/000351253

Ulrich R Kleeberg, Michael Fink, Hans-Werner Tessen, Alice Nennecke, Stefan Hentschel, Stefan Bartels

{"title":"Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer - own findings and review of the literature.","authors":"Ulrich R Kleeberg, Michael Fink, Hans-Werner Tessen, Alice Nennecke, Stefan Hentschel, Stefan Bartels","doi":"10.1159/000351253","DOIUrl":"https://doi.org/10.1159/000351253","url":null,"abstract":"Background: Adjuvant treatment concepts have improved the 10-year cure rate of breast and colon cancer, but new treatments for metastatic disease have yielded only incremental benefit. If treatments for disseminated cancer were actually prolonging life rather than only increasing remission rates, this effect should have been documented over the last 30+ years. However, published data concerning advances in treatment for disseminated cancer have been contradictory.Patients and methods: To add data-based information, we analyzed 2 sources: a regional population-based cancer registry (Hamburgisches Krebsregister, HKR), and a research cancer registry (Projektgruppe Internistische Onkologie, PIO). We compared the survival of several thousand patients with metastatic disease who received treatment only after dissemination with that of patients who received initial adjuvant therapy.Results: After adjuvant treatment, survival in patients with disseminated breast cancer is up to a third shorter than that of patients without adjuvant therapy.Conclusions: In accordance with published evidence, we conclude that ineffective adjuvant treatment shortens survival after documentation of metastatic disease. This is probably due to the elimination of chemo-sensitive tumor cells or to the induction of resistance in remaining micrometatases. This negative effect on survival after dissemination has been shown clearly for breast cancer and is also probable for cancer of the colon and other sites.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 6","pages":"348-56"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000351253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31606097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. 阿法替尼、厄洛替尼和吉非替尼在EGFR突变阳性肺腺癌一线治疗中的应用综述

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-08-19 DOI: 10.1159/000354627

Jens Köhler, Martin Schuler

{"title":"Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.","authors":"Jens Köhler, Martin Schuler","doi":"10.1159/000354627","DOIUrl":"https://doi.org/10.1159/000354627","url":null,"abstract":"Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined phenotypes that display an enormous genetic variability. In recent years, epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma has emerged as a unique subset of NSCLC in terms of etiopathogenesis and tumor biology. Since the introduction of the reversible EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, patients with metastatic EGFR mutation-positive lung cancer can be offered a therapeutic alternative that has proven its superiority over standard platinum-based chemotherapy. However, primary or acquired resistance limits the therapeutic success of these targeted agents. Irreversible inhibitors targeting all ErbB family receptor tyrosine kinases, such as afatinib and dacomitinib, have been developed to confer sustained disease control in ErbB-dependent cancers. The large LUX-Lung 3 phase III trial recently reported afatinib to be clearly superior over the most effective platinum doublet in patients with EGFR mutation-positive lung cancer. To fully exploit the clinical activity of afatinib, proactive management of its gastrointestinal and dermatologic toxicities is advised.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 9","pages":"510-8"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000354627","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31746554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 88

The impact of computed tomography on early glottic cancer outcomes. 计算机断层扫描对早期声门癌预后的影响。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-02-21 DOI: 10.1159/000348529

Waleed F Mourad, Kenneth S Hu, Rania A Shourbaji, Dan Ishihara, Wilson Lin, Mahesh Kumar, Dukagjin M Blakaj, Louis B Harrison

{"title":"The impact of computed tomography on early glottic cancer outcomes.","authors":"Waleed F Mourad, Kenneth S Hu, Rania A Shourbaji, Dan Ishihara, Wilson Lin, Mahesh Kumar, Dukagjin M Blakaj, Louis B Harrison","doi":"10.1159/000348529","DOIUrl":"https://doi.org/10.1159/000348529","url":null,"abstract":"Purpose: Aim of this study was to evaluate the impact of computed tomography (CT)-based simulation and planning on early glottic cancer outcomes and toxicity.Methods: This is a single-institution retrospective study of 253 patients with T1-2 glottic cancer who underwent radiation therapy (RT) from January 1998-2010. Group A (80%) underwent 2-dimensional RT (2DRT) and group B (20%) 3-dimensional RT (3DRT). 76% of patients in group A and 84% in group B had T1 cancer. The median dose and fraction size were 63 Gy and 2.25 Gy, respectively.Results: With a median follow-up of 83, 93, and 30 months for the whole cohort, group A and B, respectively, the loco-regional control (LRC) was 97.6%. The rate of LRC for T1 disease was 99.5% and for T2 disease 91%. According to the RT modality, rates of LRC were 99.4 and 100% in groups A and B for T1, and 89.8 and 100% for T2. Long-term toxicity was negligible in both groups. Kaplan-Meier Curve showed the 5-year cause-specific survival to be 100%. Chi-square and multivariate analysis tests showed a significant relationship between CT simulation (3DRT) and LRC (p < 0.0001).Conclusion: CT-based simulation and planning provided better LRC and less acute side effects compared to 2DRT.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 3","pages":"83-6"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000348529","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31303968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. 胰腺癌患者高强度聚焦超声的安全性评价。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-02-25 DOI: 10.1159/000348530

Kun Wang, Huili Zhu, Zhiqiang Meng, Zhen Chen, Junhua Lin, Yehua Shen, Huifeng Gao

{"title":"Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer.","authors":"Kun Wang, Huili Zhu, Zhiqiang Meng, Zhen Chen, Junhua Lin, Yehua Shen, Huifeng Gao","doi":"10.1159/000348530","DOIUrl":"https://doi.org/10.1159/000348530","url":null,"abstract":"Introduction: This study was performed to analyze the safety of high-intensity focused ultrasound (HIFU) for treating pancreatic cancer.Methods: 224 cases with advanced pancreatic cancer were enrolled into this study. Real-time sonographic images were taken, and vital signs, liver and kidney function, skin burns, local reactions, and systemic effects were monitored and recorded before, during, and after HIFU. Computed tomography or magnetic resonance imaging (MRI) was also performed before and after HIFU.Results: Serum amylase level increased in 16 cases (7.1%) 1 day after HIFU treatment, and 9 of these cases also had abnormal urinary amylase levels. Gastrointestinal (GI) dysfunction such as abdominal distension and anorexia with slight nausea was observed in 10 cases (4.5%) after HIFU treatment. 1 case with pancreatic head cancer developed obstructive jaundice 2 weeks after HIFU treatment. Vertebral injury, identified by MRI, occurred in 2 cases, although no symptoms were seen. No severe complications such as skin burns, lesion bleeding, GI tract bleeding or GI perforation were observed in any of the cases.Conclusion: For specific patients, HIFU treatment is a safe, non-invasive treatment for pancreatic cancer but requires careful preoperative preparation and exact operative performance.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 3","pages":"88-92"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000348530","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31303969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 49

[New drugs in oncology: benefits, risks and challenges]. [肿瘤新药:益处、风险和挑战]。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-07-01 DOI: 10.1159/000352000

David Cella, Volker Vervölgyi, Bernhard Wörmann

引用次数: 2

[(Mis) management in healthcare]. [医疗保健管理不善]。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-07-01 DOI: 10.1159/000352001

Friedrich Overkamp, Klaus-Peter Thiele, Martin Wilhelm

引用次数: 5